Positive Results for Diachrome Clinical Trial in People with Type 2 Diabetes
Nutrition 21 and XL Health is on track with commercialization plans of Diachrome.
This is a major clinical milestone for Diachrome and “further confirms its safety and benefits in uniquely managing both blood sugar and cholesterol levels in conjunction with pharmaceutical treatments for people with diabetes”, reports Gail Montgomery, president and CEO of Nutrition 21. “We are currently sharing the data with strategic business partners and key medical experts to enlist their support in accelerating our efforts to move Diachrome into clinical practice as a nutritional therapy for people with diabetes and at risk for heart disease.”
The companies say this is the largest US study to demonstrate the health benefits of chromium-based intervention for diabetes. The study was a pivotal randomized, double-blinded, placebo-controlled clinical trial evaluating the effects of Diachrome®, a combination of chromium picolinate and biotin, on glycated hemoglobin (HbA1c), fasting plasma glucose, cholesterol and triglyceride”, the companies say.
Chromium is a trace mineral and is essential in its role as a co-factor of insulin, Nutrition 21 says. “Between 1959 and 1977, initial observations in people with type 2 diabetes, or diabetes mellitus, led researchers to hypothesize that chromium picolinate - Nutrition 21’s form of chromium—might benefit individuals who have insulin resistant diabetes”.
“The detailed findings from the trial are being shared with a number of clinical outcomes groups at both XL Health and Nutrition 21,” said Paul Serini, executive vice president of XL Health. “Based on the positive trial results we have seen thus far and the apparent benefits to our diabetic patients’ health and medical spending, XL Health is investigating ways the Diachrome product can be incorporated on a broad scale into the work we do with CMS and Medicare Advantage patients.”
All content and features on this website are copyrighted with all rights reserved. The full details can be found in our privacy statement
